[go: up one dir, main page]

WO2006064375A2 - Composes heterocycliques a noyau a cinq elements a substitution aminoaryle pour le traitement de maladies - Google Patents

Composes heterocycliques a noyau a cinq elements a substitution aminoaryle pour le traitement de maladies Download PDF

Info

Publication number
WO2006064375A2
WO2006064375A2 PCT/IB2005/004031 IB2005004031W WO2006064375A2 WO 2006064375 A2 WO2006064375 A2 WO 2006064375A2 IB 2005004031 W IB2005004031 W IB 2005004031W WO 2006064375 A2 WO2006064375 A2 WO 2006064375A2
Authority
WO
WIPO (PCT)
Prior art keywords
membered ring
diseases
treatment
heterocyclic compounds
ring heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/004031
Other languages
English (en)
Other versions
WO2006064375A9 (fr
Inventor
Marco Ciufolini
Abdellah Benjahad
Bruno Giethlen
Alain Moussy
Camille Wermuth
Anne Lermet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of WO2006064375A2 publication Critical patent/WO2006064375A2/fr
Publication of WO2006064375A9 publication Critical patent/WO2006064375A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés choisis parmi des hétérocycles à noyau à cinq éléments aminoaryle modulant, régulant et/ou inhibant sélectivement la transduction de signal médiée par certaines tyrosine kinases natives et/ou mutantes impliquées dans une pluralité de maladies humaines et animales, telles que les maladies prolifératives, métaboliques, allergiques et dégénératives.
PCT/IB2005/004031 2004-12-16 2005-12-16 Composes heterocycliques a noyau a cinq elements a substitution aminoaryle pour le traitement de maladies Ceased WO2006064375A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63616304P 2004-12-16 2004-12-16
US60/636,163 2004-12-16

Publications (2)

Publication Number Publication Date
WO2006064375A2 true WO2006064375A2 (fr) 2006-06-22
WO2006064375A9 WO2006064375A9 (fr) 2006-08-03

Family

ID=36250764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/004031 Ceased WO2006064375A2 (fr) 2004-12-16 2005-12-16 Composes heterocycliques a noyau a cinq elements a substitution aminoaryle pour le traitement de maladies

Country Status (1)

Country Link
WO (1) WO2006064375A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026251A3 (fr) * 2005-07-14 2007-07-12 Ab Science Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
WO2007076460A3 (fr) * 2005-12-23 2007-08-16 Kalypsys Inc Nouveaux thiazole-urees substitues utiles en tant qu'inhibiteurs de proteine-kinases
WO2008065141A1 (fr) * 2006-11-30 2008-06-05 Probiodrug Ag Nouveaux inhibiteurs de glutaminylcyclase
WO2009114552A1 (fr) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Composés hétéroaryle, compositions et procédés d’utilisation dans le traitement du cancer
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
WO2011033018A1 (fr) * 2009-09-17 2011-03-24 Janssen Pharmaceutica Nv N-phényl-1-(4-pyridinyl)-1h-pyrazol-3-amines substituées
US8143419B2 (en) 2006-04-19 2012-03-27 Janssen Pharmaceutica N. V. Trisubstituted 1,2,4-triazoles
US8404851B2 (en) 2007-10-18 2013-03-26 Janssen Pharmaceutica Nv 1,3,5-trisubstituted triazole derivative
US8440701B2 (en) 2007-10-18 2013-05-14 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
US8779158B2 (en) 2008-05-09 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
US8778974B2 (en) 2008-03-19 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
EP2282636B1 (fr) 2008-05-06 2016-03-23 Novartis AG Composés de benzène sulfonamide thiazole et oxazole
CN106397432A (zh) * 2015-08-03 2017-02-15 南昌弘益科技有限公司 作为jak抑制剂的一类新化合物

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007026251A3 (fr) * 2005-07-14 2007-07-12 Ab Science Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
WO2007076460A3 (fr) * 2005-12-23 2007-08-16 Kalypsys Inc Nouveaux thiazole-urees substitues utiles en tant qu'inhibiteurs de proteine-kinases
US8143419B2 (en) 2006-04-19 2012-03-27 Janssen Pharmaceutica N. V. Trisubstituted 1,2,4-triazoles
WO2008065141A1 (fr) * 2006-11-30 2008-06-05 Probiodrug Ag Nouveaux inhibiteurs de glutaminylcyclase
US8440701B2 (en) 2007-10-18 2013-05-14 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
US8404851B2 (en) 2007-10-18 2013-03-26 Janssen Pharmaceutica Nv 1,3,5-trisubstituted triazole derivative
WO2009114552A1 (fr) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Composés hétéroaryle, compositions et procédés d’utilisation dans le traitement du cancer
US8778974B2 (en) 2008-03-19 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles
EP2282636B1 (fr) 2008-05-06 2016-03-23 Novartis AG Composés de benzène sulfonamide thiazole et oxazole
US8779158B2 (en) 2008-05-09 2014-07-15 Janssen Pharmaceutica Nv Trisubstituted pyrazoles as acetylcholine receptor modulators
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
WO2010020305A1 (fr) 2008-08-18 2010-02-25 Merck Patent Gmbh Dérivés d'oxadiazol pour le traitement du diabète
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
KR20120089805A (ko) * 2009-09-17 2012-08-13 얀센 파마슈티카 엔.브이. 치환된 ｎ-페닐-1-(4-피리디닐)-1ｈ-피라졸-3-아민
CN102574832A (zh) * 2009-09-17 2012-07-11 詹森药业有限公司 取代的n-苯基-1-(4-吡啶基)-1h-吡唑-3-胺
US8791144B2 (en) 2009-09-17 2014-07-29 Janssen Pharmaceutica Nv Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines
WO2011033018A1 (fr) * 2009-09-17 2011-03-24 Janssen Pharmaceutica Nv N-phényl-1-(4-pyridinyl)-1h-pyrazol-3-amines substituées
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
US9499497B2 (en) 2012-11-20 2016-11-22 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
CN106397432A (zh) * 2015-08-03 2017-02-15 南昌弘益科技有限公司 作为jak抑制剂的一类新化合物

Also Published As

Publication number Publication date
WO2006064375A9 (fr) 2006-08-03

Similar Documents

Publication Publication Date Title
MXPA05001277A (es) 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
WO2005040139A8 (fr) Composes de 2-aminoaryloxazole destines au traitement de maladies
WO2006064375A2 (fr) Composes heterocycliques a noyau a cinq elements a substitution aminoaryle pour le traitement de maladies
MX2012008083A (es) Inhibidores de triazol y oxazol quinaza.
BRPI0507271A (pt) 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase
WO2007109045A8 (fr) composes organiques
WO2006014325A3 (fr) Modulateurs de c-met et leur methode d'utilisation
WO2009097287A9 (fr) Composés et compositions comme inhibiteurs de kinases
WO2007013896A3 (fr) Composes modulant l'activite de c-kit et c-fms et utilisations
WO2006083673A3 (fr) Inhibiteurs des c-jun n-terminal kinases
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MX2010002004A (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
WO2006065686A3 (fr) Derives spiro utilises en tant qu'inhibiteurs de lipoxygenase
WO2005000298A3 (fr) Inhibiteurs de p-38
WO2004089286A3 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de la proteine kinase
EP1503757A4 (fr) Inhibiteurs de la tyrosine kinase
WO2008008286A3 (fr) Pyrazoles substitués servant d'antagonistes des récepteurs de la ghréline
NO20075627L (no) Inhibitorer av cytosolisk fosfolipase A2
NO20075553L (no) Substituerte oxazolderivater og deres anvendelse som tyrosinkinaseinhibitorer
PH12014500168A1 (en) Selective protein kinase inhibitors
HK1222396A1 (zh) 作为选择性蛋白质激酶抑制剂之苯并咪唑衍生物
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
CA3139156A1 (fr) Composes pour le traitement de troubles dependant de la kinase
WO2007087419A3 (fr) Hétérocyclyl-1,3-dihydro-indol-2-ones insaturées et substituées à 3-5 éléments et leurs dérivés en tant qu'inhibiteurs de kinase
WO2004050681A3 (fr) Modulateurs de kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05850759

Country of ref document: EP

Kind code of ref document: A1